Suppr超能文献

大麻的作用机制和药代动力学。

Mechanisms of Action and Pharmacokinetics of Cannabis.

机构信息

Department of Neurology, Kaiser Permanente Medical Center, Orange County, CA.

出版信息

Perm J. 2020 Dec;25:1-3. doi: 10.7812/TPP/19.200.

Abstract

At least 100 cannabis species are compounds known as cannabinoids, a molecule with a 21-carbon terpenophenolic skeleton. Cannabinoids produce more than 100 naturally occurring chemicals, the most abundant of which are Δ-9-tetrahydrocannabinol (THC), cannabidiol (CBD), terpenes, and flavonoids. THC and CBD bind with cannabinoid receptors (CB1 and CB2), which are present in the brain and many organs. Metabolism of cannabis is determined by the route of consumption. When inhaled, THC and its metabolites enter the bloodstream rapidly via the lungs; they achieve peak levels within 6 to 10 minutes and reach the brain and various organs. The bioavailability of inhaled THC is 10% to 35%. After THC is absorbed, it travels to the liver where most of it is eliminated or metabolized to 11-OH-THC or 11-COOH-THC. The remaining THC and its metabolites enter the circulation. The bioavailability of ingested THC is only 4% to 12%. THC is highly lipid soluble and is therefore rapidly taken up by fat tissue. The plasma half-life of THC is 1 to 3 days in occasional users and 5 to 13 days in chronic users. The bioavailability of CBD via inhalation is 11% to 45%, whereas that of oral CBD is 6%. CBD has high lipophilicity and therefore is rapidly distributed in the brain, adipose tissue, and other organs. CBD is hydroxylated to 7-OH-CBD and 7-COOH-CBD by cytochrome P450 enzymes CYP3A4 and CYP2C9 in the liver and is excreted mainly in feces and less in urine. The plasma half-life of CBD is 18 to 32 hours.

摘要

至少有 100 种大麻素化合物被称为大麻素,这是一种具有 21 个碳原子的萜酚骨架的分子。大麻素产生超过 100 种天然存在的化学物质,其中最丰富的是Δ-9-四氢大麻酚(THC)、大麻二酚(CBD)、萜烯和类黄酮。THC 和 CBD 与大麻素受体(CB1 和 CB2)结合,这些受体存在于大脑和许多器官中。大麻的代谢取决于消费途径。当吸入时,THC 和其代谢物通过肺部迅速进入血液;它们在 6 到 10 分钟内达到峰值水平,并到达大脑和各种器官。吸入 THC 的生物利用度为 10%至 35%。THC 被吸收后,它会转移到肝脏,其中大部分被消除或代谢为 11-OH-THC 或 11-COOH-THC。剩余的 THC 和其代谢物进入循环。摄入 THC 的生物利用度仅为 4%至 12%。THC 具有高度的脂溶性,因此很快被脂肪组织吸收。偶尔使用者的 THC 血浆半衰期为 1 至 3 天,慢性使用者为 5 至 13 天。通过吸入给予 CBD 的生物利用度为 11%至 45%,而口服 CBD 的生物利用度为 6%。CBD 具有高亲脂性,因此迅速分布在大脑、脂肪组织和其他器官中。CBD 在肝脏中被细胞色素 P450 酶 CYP3A4 和 CYP2C9 羟基化为 7-OH-CBD 和 7-COOH-CBD,并主要通过粪便排泄,较少通过尿液排泄。CBD 的血浆半衰期为 18 至 32 小时。

相似文献

1
Mechanisms of Action and Pharmacokinetics of Cannabis.
Perm J. 2020 Dec;25:1-3. doi: 10.7812/TPP/19.200.
2
Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions.
Drug Metab Dispos. 2021 Dec;49(12):1070-1080. doi: 10.1124/dmd.121.000442. Epub 2021 Sep 7.
6
Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Clin Pharmacol Ther. 2023 Sep;114(3):693-703. doi: 10.1002/cpt.2973. Epub 2023 Jun 30.
10
Cannabis and Neuropsychiatric Disorders: An Updated Review.
Acta Neurol Taiwan. 2019 Jun 15;28(2):27-39.

引用本文的文献

1
Prenatal substance exposure and infant neurodevelopment: a review of magnetic resonance imaging studies.
Front Hum Neurosci. 2025 Aug 20;19:1613084. doi: 10.3389/fnhum.2025.1613084. eCollection 2025.
2
Under the Influence: Cognitive Effects of Medical Marijuana on Developing Minds.
J Pediatr Pharmacol Ther. 2025 Aug;30(4):440-449. doi: 10.5863/JPPT-25-01209. Epub 2025 Aug 11.
4
Neutrophil extracellular traps and cannabinoids: potential in cancer metastasis.
Front Oncol. 2025 Jun 17;15:1595913. doi: 10.3389/fonc.2025.1595913. eCollection 2025.
6
Acute cannabis intoxication among the paediatric population.
Front Toxicol. 2025 Apr 14;7:1558721. doi: 10.3389/ftox.2025.1558721. eCollection 2025.
7
Association of driving with blood delta-9-tetrahydrocannabinol: a systematic review.
Int J Neuropsychopharmacol. 2025 Apr 11;28(4). doi: 10.1093/ijnp/pyaf021.
8
Cannabinoids in Chronic Pain Management: A Review of the History, Efficacy, Applications, and Risks.
Biomedicines. 2025 Feb 20;13(3):530. doi: 10.3390/biomedicines13030530.
9
An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans.
Pharmaceutics. 2025 Mar 1;17(3):319. doi: 10.3390/pharmaceutics17030319.
10
Brain Cytochrome P450: Navigating Neurological Health and Metabolic Regulation.
J Xenobiot. 2025 Mar 14;15(2):44. doi: 10.3390/jox15020044.

本文引用的文献

1
Synthetic cannabinoid receptor agonists: classification and nomenclature.
Clin Toxicol (Phila). 2020 Feb;58(2):82-98. doi: 10.1080/15563650.2019.1661425. Epub 2019 Sep 16.
2
Transfer of Inhaled Cannabis Into Human Breast Milk.
Obstet Gynecol. 2018 May;131(5):783-788. doi: 10.1097/AOG.0000000000002575.
4
Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy.
Cannabis Cannabinoid Res. 2016 Mar 1;1(1):90-101. doi: 10.1089/can.2015.0012. eCollection 2016.
5
Acute Toxicity Associated with Use of 5F-Derivations of Synthetic Cannabinoid Receptor Agonists with Analytical Confirmation.
J Med Toxicol. 2016 Dec;12(4):396-401. doi: 10.1007/s13181-016-0571-7. Epub 2016 Jul 25.
6
A potted history.
Nature. 2015 Sep 24;525(7570):S10-1. doi: 10.1038/525S10a.
7
Cannabinoids in the Treatment of Epilepsy.
N Engl J Med. 2015 Sep 10;373(11):1048-58. doi: 10.1056/NEJMra1407304.
8
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22.
9
The case for medical marijuana in epilepsy.
Epilepsia. 2014 Jun;55(6):783-6. doi: 10.1111/epi.12610. Epub 2014 May 22.
10
Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review.
Drug Metab Rev. 2014 Feb;46(1):86-95. doi: 10.3109/03602532.2013.849268. Epub 2013 Oct 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验